Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30185800 | 1.00 | CASP3 (0.51) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL30185803 | 1.00 | CASP3 (0.51) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL118016 | 0.90 | KMT2A (0.57) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL30208674 | 0.90 | KMT2A (0.57) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL24899351 | 0.86 | CASP3 (0.48) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL20299865 | 0.86 | CASP3 (0.48) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL30229458 | 0.86 | CASP3 (0.48) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL20299866 | 0.86 | CASP3 (0.48) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL31688935 | 0.86 | CASP3 (0.48) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL30009709 | 0.86 | CASP3 (0.48) | CASP3MDM2MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4168121-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115702026-A | Macrocyclic compounds and methods of use thereof | 基因泰克公司 | 2023-02-14 | — | — | CN | disclosed |
| US-20160314241-A1 | DRUG DISCOVERY METHOD | Keddem Bioscience Ltd. (IL) | 2016-10-27 | — | — | US | disclosed |
| US-9405885-B2 | Drug discovery method | Keddem Bioscience Ltd. (IL) | 2016-08-02 | — | — | US | disclosed |
| EP-2581849-A1 | Drug discovery method | KEDDEM BIO-SCIENCE LTD. (IL) | 2013-04-17 | — | — | EP | disclosed |
| US-8019550-B2 | Drug discovery method | Keddem Bioscience Ltd. (IL) | 2011-09-13 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1799222-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006030323-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | CASP3 53/4885MDM2 685/4885MDM4 1699/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | CASP3 2910/4885MDM2 917/4885MDM4 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.